Все продукты предназначены исключительно для научно-исследовательских целей — не для употребления человеком.
PeptideRU
Weight Loss Research

AOD-9604

Modified C-terminal fragment of human growth hormone studied for selective fat-cell lipolysis without the blood sugar or anabolic side-effects of full-length HGH. Received FDA GRAS status for oral formulation.

2 поставщиков в России·1 с доставкой в Россию
Исследовательское соединение: AOD-9604 продаётся для научных исследований. Он не является одобренным лекарством. Описанные эффекты основаны на опубликованных доклинических и (при наличии) клинических исследованиях — не замена медицинской консультации.

Что Показывают Исследования

Studied for β3-adrenergic receptor-mediated lipolysis and lipogenesis inhibition in diet-induced obesity models, without IGF-1 receptor binding. Studies measure fat mass by DXA, serum free fatty acids, and glycerol release from adipose explants. Selective fat-targeting mechanism with favourable safety profile in published trials.

Плюсы и Минусы

Преимущества
  • +AOD-9604 received FDA GRAS (Generally Recognised As Safe) status for oral use — favourable regulatory safety signal
  • +CJC-1295 DAC requires only once-weekly dosing due to its 6–8 day half-life — highly convenient vs. daily protocols
  • +Ipamorelin is the most selective GH secretagogue available: no cortisol, prolactin, or ACTH elevation at standard doses
  • +CJC-1295 has published Phase I and II human trial data with well-characterised GH/IGF-1 pharmacokinetics
  • +AOD-9604 selectively activates β3 receptors in fat cells without binding IGF-1 receptors — no anabolic side-effects
  • +Combination of CJC-1295 + Ipamorelin produces 2–5× greater GH pulse than either compound alone
Ограничения и Риски
  • All three compounds require subcutaneous injection — no oral route with established human bioavailability
  • CJC-1295 substantially raises IGF-1 levels: blood glucose monitoring is advisable, especially for pre-diabetic individuals
  • AOD-9604 Phase III obesity trials showed limited efficacy at the doses tested orally — systemic injectable effects differ
  • Body composition improvements require consistent use over weeks to months — not a rapid intervention
  • Russian availability is currently limited: only Particle Peptides consistently stocks all three in 2026
  • GH elevation during sleep can disrupt sleep architecture if dosed too close to bedtime

Хронология Эффектов

На основе временных рамок опубликованных исследований. Экстраполяция на человека является приблизительной — индивидуальные результаты значительно варьируются.

Начало
Weeks 2–4
Максимальный Эффект
Weeks 6–12
Контекст

GH serum elevation from CJC-1295 is detectable within 24 hours of first injection. Measurable body composition changes (DXA-measured fat mass reduction) in animal models require 4–6 weeks at minimum. Human self-researcher timelines are typically 8–12 weeks before significant changes in body composition become visible.

Для Чего Исследуют

Stubborn body fat reduction, particularly visceral/abdominal fat
Improving body composition ratio (lean mass vs fat mass)
Growth hormone optimisation without exogenous HGH
CJC-1295 + Ipamorelin combination stack for synergistic GH secretion
Metabolic rate and fat oxidation research
Recovery and sleep quality improvement (GH pulses occur during deep sleep)
Правовой Статус в России: AOD-9604 is unscheduled and not a controlled substance in Russia. CJC-1295 and Ipamorelin are on the WADA Prohibited List (S2 — Peptide Hormones) for competitive athletes. They are not approved medicines in Russia or USA. Purchase as research compounds is legal in Russia for non-competitive research purposes. Athletes subject to testing should be aware of detection windows.

Практические Вопросы

Только в образовательных целях. Самостоятельное введение исследовательских соединений сопряжено со значительными рисками. Проконсультируйтесь с квалифицированным специалистом.

When is the best time to inject CJC-1295 + Ipamorelin?

Published animal studies and the CJC-1295 Phase I trial use a single weekly or biweekly SC injection without time-of-day specification. The self-research community commonly doses Ipamorelin immediately before sleep, as natural GH secretion is highest during slow-wave sleep — and GH secretagogues amplify this natural pulse. CJC-1295 DAC is typically injected once weekly at any time due to its extended half-life.

Is AOD-9604 a safer alternative to HGH for fat loss?

AOD-9604 was specifically engineered to retain the lipolytic (fat-burning) activity of growth hormone while eliminating its anabolic and diabetogenic effects. It does not bind the IGF-1 receptor and does not significantly alter blood glucose in published studies — key advantages over full-length HGH. However, "safer" must be understood in context: AOD-9604 has no long-term human safety data for injectable use, and the FDA GRAS designation applies to an oral formulation, not injectable.

Do I need to cycle off CJC-1295 and Ipamorelin?

Published human trials ran for 4–6 weeks without tolerance or desensitisation issues. The self-research community commonly uses 3-month on / 1-month off cycles, though this is convention rather than evidence-based protocol. There is theoretical concern that chronic GHRH receptor stimulation could cause pituitary desensitisation over very long periods — a risk that has not been systematically studied at research peptide doses.

Где Купить AOD-9604 в России

2 поставщиков с доступом к России в настоящее время имеет в наличии AOD-9604, включая 1 с подтверждённой доставкой в Россию. Сравните цены и наличие ниже.